Proton Pump Inhibitors (PPIs) Market by Product and Geography - Global Forecast and Analysis 2019-2023
SKU ID :TNV-13658375 | Published Date: 24-Jun-2019 | No. of pages: 127Description
TOC
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
2.1 Preface
2.2 Preface
2.3 Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
Market ecosystem
Market characteristics
Market segmentation analysis
PART 04: MARKET SIZING
Market definition
Market sizing 2018
Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
Bargaining power of buyers
Bargaining power of suppliers
Threat of new entrants
Threat of substitutes
Threat of rivalry
Market condition
PART 06: MARKET SEGMENTATION BY PRODUCT
Market segmentation by product
Comparison by product
OTC PPIs - Market size and forecast 2018-2023
Prescription PPIs - Market size and forecast 2018-2023
Market opportunity by product
PART 07: CUSTOMER LANDSCAPE
PART 08: GEOGRAPHIC LANDSCAPE
Geographic segmentation
Geographic comparison
North America - Market size and forecast 2018-2023
Europe - Market size and forecast 2018-2023
Asia - Market size and forecast 2018-2023
ROW - Market size and forecast 2018-2023
Key leading countries
Market opportunity
PART 09: DECISION FRAMEWORK
PART 10: DRIVERS AND CHALLENGES
Market drivers
Market challenges
PART 11: MARKET TRENDS
Growing geriatric population
Rising prevalence of obesity
Rising utilization of PPIs
PART 12: VENDOR LANDSCAPE
Overview
Landscape disruption
Competitive scenario
PART 13: VENDOR ANALYSIS
Vendors covered
Vendor classification
Market positioning of vendors
AstraZeneca Plc
Bayer AG
Johnson & Johnson Services Inc.
Pfizer Inc.
Takeda Pharmaceutical Co. Ltd.
PART 14: APPENDIX
Research methodology
List of abbreviations
Definition of market positioning of vendors
PART 15: EXPLORE TECHNAVIO
Exhibit 01: Global pharmaceuticals market
Exhibit 02: Segments of global pharmaceuticals market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Market definition - Inclusions and exclusions checklist
Exhibit 06: Market size 2018
Exhibit 07: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 08: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 09: Five forces analysis 2018
Exhibit 10: Five forces analysis 2023
Exhibit 11: Bargaining power of buyers
Exhibit 12: Bargaining power of suppliers
Exhibit 13: Threat of new entrants
Exhibit 14: Threat of substitutes
Exhibit 15: Threat of rivalry
Exhibit 16: Market condition - Five forces 2018
Exhibit 17: Product - Market share 2018-2023 (%)
Exhibit 18: Comparison by product
Exhibit 19: OTC PPIs - Market size and forecast 2018-2023 ($ millions)
Exhibit 20: OTC PPIs - Year-over-year growth 2019-2023 (%)
Exhibit 21: Prescription PPIs - Market size and forecast 2018-2023 ($ millions)
Exhibit 22: Prescription PPIs - Year-over-year growth 2019-2023 (%)
Exhibit 23: Market opportunity by product
Exhibit 24: Customer landscape
Exhibit 25: Market share by geography 2018-2023 (%)
Exhibit 26: Geographic comparison
Exhibit 27: North America - Market size and forecast 2018-2023 ($ millions)
Exhibit 28: North America - Year-over-year growth 2019-2023 (%)
Exhibit 29: Top 3 countries in North America
Exhibit 30: Europe - Market size and forecast 2018-2023 ($ millions)
Exhibit 31: Europe - Year-over-year growth 2019-2023 (%)
Exhibit 32: Top 3 countries in Europe
Exhibit 33: Asia - Market size and forecast 2018-2023 ($ millions)
Exhibit 34: Asia - Year-over-year growth 2019-2023 (%)
Exhibit 35: Top 3 countries in Asia
Exhibit 36: ROW - Market size and forecast 2018-2023 ($ millions)
Exhibit 37: ROW - Year-over-year growth 2019-2023 (%)
Exhibit 38: Top 3 countries in ROW
Exhibit 39: Key leading countries
Exhibit 40: Market opportunity
Exhibit 41: Use of PPIs in different patient settings in 2010
Exhibit 42: Sales of Takeda’s PPIs after the launch of generics ($ millions)
Exhibit 43: Impact of drivers and challenges
Exhibit 44: Vendor landscape
Exhibit 45: Landscape disruption
Exhibit 46: Vendors covered
Exhibit 47: Vendor classification
Exhibit 48: Market positioning of vendors
Exhibit 49: AstraZeneca Plc - Vendor overview
Exhibit 50: AstraZeneca Plc - Product segments
Exhibit 51: AstraZeneca Plc - Organizational developments
Exhibit 52: AstraZeneca Plc - Geographic focus
Exhibit 53: AstraZeneca Plc - Key offerings
Exhibit 54: AstraZeneca Plc - Key customers
Exhibit 55: Bayer AG - Vendor overview
Exhibit 56: Bayer AG - Product segments
Exhibit 57: Bayer AG - Organizational developments
Exhibit 58: Bayer AG - Geographic focus
Exhibit 59: Bayer AG - Segment focus
Exhibit 60: Bayer AG - Key offerings
Exhibit 61: Bayer AG - Key customers
Exhibit 62: Johnson & Johnson Services Inc. - Vendor overview
Exhibit 63: Johnson & Johnson Services Inc. - Business segments
Exhibit 64: Johnson & Johnson Services Inc. - Organizational developments
Exhibit 65: Johnson & Johnson Services Inc. - Geographic focus
Exhibit 66: Johnson & Johnson Services Inc. - Segment focus
Exhibit 67: Johnson & Johnson Services Inc. - Key offerings
Exhibit 68: Johnson & Johnson Services Inc. - Key customers
Exhibit 69: Pfizer Inc. - Vendor overview
Exhibit 70: Pfizer Inc. - Business segments
Exhibit 71: Pfizer Inc. - Organizational developments
Exhibit 72: Pfizer Inc. - Geographic focus
Exhibit 73: Pfizer Inc. - Segment focus
Exhibit 74: Pfizer Inc. - Key offerings
Exhibit 75: Pfizer Inc. - Key customers
Exhibit 76: Takeda Pharmaceutical Co. Ltd. - Vendor overview
Exhibit 77: Takeda Pharmaceutical Co. Ltd. - Business segments
Exhibit 78: Takeda Pharmaceutical Co. Ltd. - Organizational developments
Exhibit 79: Takeda Pharmaceutical Co. Ltd. - Geographic focus
Exhibit 80: Takeda Pharmaceutical Co. Ltd. - Key offerings
Exhibit 81: Takeda Pharmaceutical Co. Ltd. - Key customers
Exhibit 82: Validation techniques employed for market sizing
Exhibit 83: Definition of market positioning of vendors
Tables & Figures
Companies
AstraZeneca Plc
Bayer AG
Johnson & Johnson Services Inc.
Pfizer Inc.
Takeda Pharmaceutical Co. Ltd.
- PRICE
-
$2500$4000